Actively Recruiting
A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Biologic Effect of VG2062 in Patients With Solid Tumors
Led by Shanghai Virogin Biotech Co., Ltd. · Updated on 2026-03-25
30
Participants Needed
1
Research Sites
123 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
VG2062 is a Recombinant Human IL12/15 Dual-Regulated Oncolytic HSV-1 Injection. This Phase I study will be conducted in herpes simplex virus (HSV) -seropositive subjects with advanced malignant solid tumors that are refractory to conventional therapies. This is an open label study to determine the safety and tolerability of VG2062, and recommended dose of VG2062 for Phase II trials.
CONDITIONS
Official Title
A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Biologic Effect of VG2062 in Patients With Solid Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Signed written informed consent form.
- Age 18 to 75 years (inclusive), male or female.
- Have advanced malignant solid tumors that have failed standard treatment with no effective treatment available.
- Patients of childbearing potential must agree to use reliable contraception during the trial and for at least 90 days after dosing.
- Females of childbearing potential must have a negative blood pregnancy test within 7 days before enrollment.
You will not qualify if you...
- Received other unlisted drug clinical trial treatments within 4 weeks before the first dose.
- Underwent major organ surgery (excluding needle biopsy) or had significant trauma within 4 weeks before the first dose.
- Currently experiencing herpes simplex virus recurrence or infection with symptoms such as oral herpes labialis, herpetic keratitis, herpetic dermatitis, or genital herpes.
- Have other active uncontrolled infections.
- Known alcohol or drug dependence.
- Have mental disorders or poor compliance.
- Are pregnant or breastfeeding.
- Considered unsuitable for the clinical study by the investigator due to serious systemic diseases or other reasons.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
No. 67, Huayuan Road, Langfang Economic and Technological Development Zone, Hebei Province
Hebei, China
Actively Recruiting
Research Team
S
Shu hang Wang
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here